Mechanistic insights into the rational design of masked antibodies

Although monoclonal antibodies have greatly improved cancer therapy, they can trigger side effects due to on-target, off-tumor toxicity. Over the past decade, strategies have emerged to successfully mask the antigen-binding site of antibodies, such that they are only activated at the relevant site,...

Full description

Saved in:
Bibliographic Details
Published in:mAbs Vol. 14; no. 1; p. 2095701
Main Authors: Orozco, Carolina T., Bersellini, Manuela, Irving, Lorraine M., Howard, Wesley W., Hargreaves, David, Devine, Paul W. A., Siouve, Elise, Browne, Gareth J., Bond, Nicholas J., Phillips, Jonathan J., Ravn, Peter, Jackson, Sophie E.
Format: Journal Article
Language:English
Published: Taylor & Francis 31-12-2022
Taylor & Francis Group
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Although monoclonal antibodies have greatly improved cancer therapy, they can trigger side effects due to on-target, off-tumor toxicity. Over the past decade, strategies have emerged to successfully mask the antigen-binding site of antibodies, such that they are only activated at the relevant site, for example, after proteolytic cleavage. However, the methods for designing an ideal affinity-based mask and what parameters are important are not yet well understood. Here, we undertook mechanistic studies using three masks with different properties and identified four critical factors: binding site and affinity, as well as association and dissociation rate constants, which also played an important role. HDX-MS was used to identify the location of binding sites on the antibody, which were subsequently validated by obtaining a high-resolution crystal structure for one of the mask-antibody complexes. These findings will inform future designs of optimal affinity-based masks for antibodies and other therapeutic proteins.
AbstractList Although monoclonal antibodies have greatly improved cancer therapy, they can trigger side effects due to on-target, off-tumor toxicity. Over the past decade, strategies have emerged to successfully mask the antigen-binding site of antibodies, such that they are only activated at the relevant site, for example, after proteolytic cleavage. However, the methods for designing an ideal affinity-based mask and what parameters are important are not yet well understood. Here, we undertook mechanistic studies using three masks with different properties and identified four critical factors: binding site and affinity, as well as association and dissociation rate constants, which also played an important role. HDX-MS was used to identify the location of binding sites on the antibody, which were subsequently validated by obtaining a high-resolution crystal structure for one of the mask-antibody complexes. These findings will inform future designs of optimal affinity-based masks for antibodies and other therapeutic proteins.
Author Hargreaves, David
Ravn, Peter
Siouve, Elise
Orozco, Carolina T.
Bond, Nicholas J.
Jackson, Sophie E.
Irving, Lorraine M.
Howard, Wesley W.
Browne, Gareth J.
Bersellini, Manuela
Phillips, Jonathan J.
Devine, Paul W. A.
Author_xml – sequence: 1
  givenname: Carolina T.
  orcidid: 0000-0001-7274-8833
  surname: Orozco
  fullname: Orozco, Carolina T.
  organization: Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK, Biologics Engineering, R&D, AstraZeneca, Cambridge, UK, Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Cambridge, UK
– sequence: 2
  givenname: Manuela
  surname: Bersellini
  fullname: Bersellini, Manuela
  organization: Biologics Engineering, R&D, AstraZeneca, Cambridge, UK
– sequence: 3
  givenname: Lorraine M.
  orcidid: 0000-0002-0816-5729
  surname: Irving
  fullname: Irving, Lorraine M.
  organization: Biologics Engineering, R&D, AstraZeneca, Cambridge, UK
– sequence: 4
  givenname: Wesley W.
  orcidid: 0000-0001-8314-8454
  surname: Howard
  fullname: Howard, Wesley W.
  organization: Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, MD, USA
– sequence: 5
  givenname: David
  orcidid: 0000-0003-4441-0039
  surname: Hargreaves
  fullname: Hargreaves, David
  organization: Discovery Sciences, R&D, AstraZeneca, Cambridge, UK
– sequence: 6
  givenname: Paul W. A.
  surname: Devine
  fullname: Devine, Paul W. A.
  organization: Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Cambridge, UK
– sequence: 7
  givenname: Elise
  orcidid: 0000-0001-8254-6610
  surname: Siouve
  fullname: Siouve, Elise
  organization: Biologics Engineering, R&D, AstraZeneca, Cambridge, UK, Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK
– sequence: 8
  givenname: Gareth J.
  orcidid: 0000-0002-4579-2625
  surname: Browne
  fullname: Browne, Gareth J.
  organization: Biologics Engineering, R&D, AstraZeneca, Cambridge, UK
– sequence: 9
  givenname: Nicholas J.
  orcidid: 0000-0002-0312-7360
  surname: Bond
  fullname: Bond, Nicholas J.
  organization: Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Cambridge, UK
– sequence: 10
  givenname: Jonathan J.
  orcidid: 0000-0002-5361-9582
  surname: Phillips
  fullname: Phillips, Jonathan J.
  organization: Living Systems Institute, University of Exeter, Exeter, UK
– sequence: 11
  givenname: Peter
  orcidid: 0000-0003-3032-9037
  surname: Ravn
  fullname: Ravn, Peter
  organization: Biologics Engineering, R&D, AstraZeneca, Cambridge, UK, Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark
– sequence: 12
  givenname: Sophie E.
  orcidid: 0000-0002-7470-9800
  surname: Jackson
  fullname: Jackson, Sophie E.
  organization: Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK
BookMark eNpVkU1vFDEMhiNUREvpT0CaI5ct-f64IEHFR6UiLnCOPIlnN2U2KUkWiX_PDLtUqg-2Zb96LOt9Sc5yyUjIa0avGbX0LXOSU6v5Nad8TU4Zyp6Ri3W-odbQs8de83Ny1do9XWNRGfqCnAtlnBPcXpAPXzHsIKfWUxhSbmm7621pehn6DocKPZUM8xBxWeWhTMMe2k-MA-SexhITtlfk-QRzw6tTvSQ_Pn38fvNlc_ft8-3N-7tNkEr2zWhRa9RSWJTWCaV0QAxBBxNH0FRpJlkwkiEojRyVAstE4HKKIARKJi7J7ZEbC9z7h5r2UP_4Asn_G5S69VCXN2b0KHmMwgUjRJRBq1FQJh3VMGnOucSF9e7IejiMe4wBc68wP4E-3eS089vy2ztuuBVqAbw5AWr5dcDW_T61gPMMGcuhea6tMdwxRxepOkpDLa1VnB7PMOpXO_1_O_1qpz_ZKf4Cx_KSdA
CitedBy_id crossref_primary_10_1021_acs_bioconjchem_4c00212
crossref_primary_10_1021_acschembio_3c00449
crossref_primary_10_1021_acs_bioconjchem_3c00374
crossref_primary_10_1021_acs_chemrev_2c00915
Cites_doi 10.1080/14712598.2020.1699053
10.1016/j.jconrel.2012.05.035
10.1038/sj.bjc.6601825
10.1038/nsmb.2154
10.1038/s41467-021-22980-w
10.1038/nrclinonc.2016.25
10.1021/acscentsci.9b00964
10.3390/antib9030034
10.1038/s41422-021-00543-4
10.4161/mabs.29865
10.1038/s41598-017-11886-7
10.1107/S0021889807021206
10.1016/j.tips.2016.10.005
10.1016/j.jmb.2007.05.022
10.1074/jbc.M112.426288
10.1002/bit.27111
10.1097/j.pain.0000000000000810
10.1038/srep38644
10.5772/35797
10.1038/nrd3003
10.1080/19420862.2020.1792130
10.1126/scitranslmed.3006682
10.1172/JCI123391
10.1038/nrc2106
10.4161/cbt.8.22.9765
10.1517/14712598.2014.920814
10.1089/jir.2018.0129
10.1002/cpt.1985
10.1002/art.39232
10.1016/j.drudis.2022.03.011
10.1016/0022-1759(92)90104-2
10.1039/c3sc22033h
10.1016/j.vaccine.2009.05.067
10.1002/btpr.1809
10.1038/ncomms5388
10.1038/s41467-020-16838-w
10.1002/cbic.201900241
10.1107/S0907444911001314
10.1093/protein/gzs064
10.1016/j.cardfail.2008.02.002
10.1021/acschembio.8b00171
10.1038/nature01392
10.1021/ja066780e
10.1107/S0907444911007773
10.1038/s41587-019-0135-x
10.1371/journal.pbio.3000286
10.1021/acscentsci.0c01448
10.1186/s12929-020-00652-z
10.1107/S0907444910007493
ContentType Journal Article
Copyright 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 The Author(s)
Copyright_xml – notice: 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 The Author(s)
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1080/19420862.2022.2095701
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate C. T. OROZCO ET AL
EISSN 1942-0870
EndPage 2095701
ExternalDocumentID oai_doaj_org_article_e42dd39c733d4c65b3014906af62224e
10_1080_19420862_2022_2095701
GroupedDBID ---
00X
0YH
53G
AAYXX
ABCCY
ABFIM
ABPEM
ACGFS
ACTIO
ADBBV
ADCVX
AEGYZ
AEISY
AENEX
AIJEM
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AQRUH
BABNJ
BAWUL
BLEHA
CCCUG
CITATION
DGEBU
DIK
DKSSO
E3Z
EBS
EMOBN
F5P
GROUPED_DOAJ
H13
HYE
KTTOD
KYCEM
LJTGL
M4Z
O9-
OK1
RPM
SV3
TDBHL
TFL
TFT
TFW
TR2
7X8
5PM
ID FETCH-LOGICAL-c454t-b8e66e6438e4893556ceecc6c7dba6056141c741ea56e2e55a813c24fda33e413
IEDL.DBID RPM
ISSN 1942-0862
IngestDate Tue Oct 22 15:05:58 EDT 2024
Tue Sep 17 21:11:36 EDT 2024
Sat Oct 05 04:16:52 EDT 2024
Fri Aug 23 02:12:53 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c454t-b8e66e6438e4893556ceecc6c7dba6056141c741ea56e2e55a813c24fda33e413
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-8254-6610
0000-0002-4579-2625
0000-0003-4441-0039
0000-0002-5361-9582
0000-0003-3032-9037
0000-0001-8314-8454
0000-0001-7274-8833
0000-0002-0816-5729
0000-0002-0312-7360
0000-0002-7470-9800
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272835/
PMID 35799328
PQID 2687729190
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_e42dd39c733d4c65b3014906af62224e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9272835
proquest_miscellaneous_2687729190
crossref_primary_10_1080_19420862_2022_2095701
PublicationCentury 2000
PublicationDate 2022-12-31
PublicationDateYYYYMMDD 2022-12-31
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-31
  day: 31
PublicationDecade 2020
PublicationTitle mAbs
PublicationYear 2022
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References e_1_3_4_3_1
e_1_3_4_9_1
e_1_3_4_42_1
e_1_3_4_7_1
e_1_3_4_40_1
e_1_3_4_5_1
e_1_3_4_23_1
e_1_3_4_21_1
e_1_3_4_44_1
e_1_3_4_27_1
e_1_3_4_25_1
e_1_3_4_48_1
e_1_3_4_29_1
e_1_3_4_30_1
e_1_3_4_51_1
e_1_3_4_13_1
e_1_3_4_34_1
e_1_3_4_11_1
e_1_3_4_32_1
e_1_3_4_17_1
e_1_3_4_38_1
e_1_3_4_15_1
e_1_3_4_36_1
e_1_3_4_19_1
e_1_3_4_4_1
e_1_3_4_2_1
e_1_3_4_8_1
e_1_3_4_20_1
e_1_3_4_41_1
e_1_3_4_6_1
e_1_3_4_24_1
e_1_3_4_45_1
e_1_3_4_22_1
e_1_3_4_43_1
e_1_3_4_28_1
e_1_3_4_49_1
e_1_3_4_26_1
e_1_3_4_47_1
Tate J (e_1_3_4_46_1) 2004; 25
e_1_3_4_31_1
e_1_3_4_50_1
e_1_3_4_12_1
e_1_3_4_35_1
e_1_3_4_10_1
e_1_3_4_33_1
e_1_3_4_16_1
e_1_3_4_39_1
e_1_3_4_14_1
e_1_3_4_37_1
e_1_3_4_18_1
References_xml – ident: e_1_3_4_7_1
  doi: 10.1080/14712598.2020.1699053
– ident: e_1_3_4_11_1
  doi: 10.1016/j.jconrel.2012.05.035
– ident: e_1_3_4_31_1
  doi: 10.1038/sj.bjc.6601825
– ident: e_1_3_4_40_1
  doi: 10.1038/nsmb.2154
– ident: e_1_3_4_33_1
  doi: 10.1038/s41467-021-22980-w
– ident: e_1_3_4_2_1
  doi: 10.1038/nrclinonc.2016.25
– ident: e_1_3_4_19_1
  doi: 10.1021/acscentsci.9b00964
– ident: e_1_3_4_3_1
  doi: 10.3390/antib9030034
– ident: e_1_3_4_35_1
  doi: 10.1038/s41422-021-00543-4
– ident: e_1_3_4_38_1
  doi: 10.4161/mabs.29865
– ident: e_1_3_4_21_1
  doi: 10.1038/s41598-017-11886-7
– ident: e_1_3_4_49_1
  doi: 10.1107/S0021889807021206
– ident: e_1_3_4_4_1
  doi: 10.1016/j.tips.2016.10.005
– ident: e_1_3_4_42_1
  doi: 10.1016/j.jmb.2007.05.022
– ident: e_1_3_4_36_1
  doi: 10.1074/jbc.M112.426288
– volume: 25
  start-page: 105
  year: 2004
  ident: e_1_3_4_46_1
  article-title: Interferences in Immunoassay
  publication-title: Clin Biochem Rev
  contributor:
    fullname: Tate J
– ident: e_1_3_4_16_1
  doi: 10.1002/bit.27111
– ident: e_1_3_4_44_1
  doi: 10.1097/j.pain.0000000000000810
– ident: e_1_3_4_39_1
  doi: 10.1038/srep38644
– ident: e_1_3_4_45_1
  doi: 10.5772/35797
– ident: e_1_3_4_5_1
  doi: 10.1038/nrd3003
– ident: e_1_3_4_15_1
  doi: 10.1080/19420862.2020.1792130
– ident: e_1_3_4_9_1
  doi: 10.1126/scitranslmed.3006682
– ident: e_1_3_4_13_1
  doi: 10.1172/JCI123391
– ident: e_1_3_4_29_1
  doi: 10.1038/nrc2106
– ident: e_1_3_4_25_1
  doi: 10.4161/cbt.8.22.9765
– ident: e_1_3_4_6_1
  doi: 10.1517/14712598.2014.920814
– ident: e_1_3_4_34_1
  doi: 10.1089/jir.2018.0129
– ident: e_1_3_4_10_1
  doi: 10.1002/cpt.1985
– ident: e_1_3_4_12_1
  doi: 10.1002/art.39232
– ident: e_1_3_4_23_1
  doi: 10.1016/j.drudis.2022.03.011
– ident: e_1_3_4_47_1
  doi: 10.1016/0022-1759(92)90104-2
– ident: e_1_3_4_20_1
  doi: 10.1039/c3sc22033h
– ident: e_1_3_4_32_1
  doi: 10.1016/j.vaccine.2009.05.067
– ident: e_1_3_4_43_1
  doi: 10.1002/btpr.1809
– ident: e_1_3_4_24_1
  doi: 10.1038/ncomms5388
– ident: e_1_3_4_14_1
  doi: 10.1038/s41467-020-16838-w
– ident: e_1_3_4_18_1
  doi: 10.1002/cbic.201900241
– ident: e_1_3_4_51_1
  doi: 10.1107/S0907444911001314
– ident: e_1_3_4_27_1
  doi: 10.1093/protein/gzs064
– ident: e_1_3_4_30_1
  doi: 10.1016/j.cardfail.2008.02.002
– ident: e_1_3_4_28_1
  doi: 10.1021/acschembio.8b00171
– ident: e_1_3_4_41_1
  doi: 10.1038/nature01392
– ident: e_1_3_4_37_1
  doi: 10.1021/ja066780e
– ident: e_1_3_4_48_1
  doi: 10.1107/S0907444911007773
– ident: e_1_3_4_17_1
  doi: 10.1038/s41587-019-0135-x
– ident: e_1_3_4_26_1
  doi: 10.1371/journal.pbio.3000286
– ident: e_1_3_4_22_1
  doi: 10.1021/acscentsci.0c01448
– ident: e_1_3_4_8_1
  doi: 10.1186/s12929-020-00652-z
– ident: e_1_3_4_50_1
  doi: 10.1107/S0907444910007493
SSID ssj0000070170
Score 2.3995903
Snippet Although monoclonal antibodies have greatly improved cancer therapy, they can trigger side effects due to on-target, off-tumor toxicity. Over the past decade,...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 2095701
SubjectTerms Masked antibodies
off-tumor cytotoxicity
pro-antibody
pro-drug
protein design
protein-protein interaction
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1NS8QwEIaDevIifuL6RQTxZLXbpEl6dHXFiyKo4K2kySwuYivb3YP_3pm0VXvy4qWENNB2Ju280yRPGDsBh53EqCwqilhGUgBgScWRMwqEE8aogMy_fdT3L-Z6TJic762-aE5YgwduDHcBMvFeZE4L4aVTaUE5QBYrO1EY2iSEr29sfiVTjfDVBIYJQ8oyiUi3d8t3THxBdVSF6WFChyzV7aYwXWAK_P6e6OxPmfwVg27W2VorHvllc9MbbAnKTXb60NCnP8_4089iqvqMn_KHHy715xYb3QEt8w1kZj4ta0rLayzMK44qkM_a34Lch0kdvJrwd1u_gedo_GlR0XTDbfZ8M366uo3aLRQiJ1M5jwoDSgGqDgNEmUlThUHROeW0L6wKGNChQ1EBNlWQQJpaMxQukRNvhQAMcDtspaxK2GXcYbsMxYTPjJAFhjVLck9rYtBZN7EDdt7ZL_9oSBn5sAWQdgbPyeB5a_ABG5GVvxsT6DpUoPvz1v35X-4fsOPORzm-GDTaYUuoFnWeKEOZAwqeAdM95_Wu2D9TTl8DYjtLNIHo9v7jFvfZKj12Q4c8YCvz2QIO2XLtF0eh034BeZTskg
  priority: 102
  providerName: Directory of Open Access Journals
Title Mechanistic insights into the rational design of masked antibodies
URI https://search.proquest.com/docview/2687729190
https://pubmed.ncbi.nlm.nih.gov/PMC9272835
https://doaj.org/article/e42dd39c733d4c65b3014906af62224e
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Lb5wwEIdH3RyqXKq2adXtI3KkKKewD_zAHJs0US6JVmoq9YaMPduumoVo2T3kv--MgWa59oIsYwSMjeY3ePwZ4BQ9DRJr8qQsZypREpFKZpZ4a1B6aa2JyPyb79ndT_vtijE5ul8LE5P2fbmaVA_rSbX6HXMrH9d-2ueJTRe3l3maMSZsOoIRacO9EL3VvBkzYeJsskoTluz9yh07m3IdV1FkmPIh19T6EF5KnZGn5j3Z99xTpPgPpOcwcXLPE12_hledhBRf20d9Ay-wegtni5ZB_XQu7p-XVDXn4kwsnunUT0dwcYu82DfymcWqajg4b6iwrQVpQbHpfg6KEFM7RL0Ua9f8wSCoC1ZlzUmH7-DH9dX95U3SbaSQeKXVNiktGoOkPSwya0ZrQ67Re-OzUDoTYaBzT9ICnTaYotbOzqVP1TI4KZHc3Hs4qOoKP4Dw1C4nSRFyK1VJzs2x6MsyJtE5v3RjmPT2Kx5bXkYx7zCkve0Ltn3R2X4MF2zlf40Zdx0r6s2vouv0AlUagsx9JmVQ3uiSA8F8ZtzSkL5ROIaTvo8K-jx4zsNVWO-aIjWW4weSPWPIBp03uOPwDI27CNruxtnH_77yExzyu7ZgyM9wsN3s8AuMmrA7jsH_cRy6fwEQ4O7P
link.rule.ids 230,315,729,782,786,866,887,2108,27935,27936,53803,53805
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-xIcFe-EaUTyOhPS1tGn_EeWRjUxHrVIki8RY5zhUqaDI17cP-e-6chLWve4ks21Fk_2zd7-K7nwE-oadFYk0WFUWsIiURqWTiyFuD0ktrTZDMn3xPr37aL-csk6P7XJgQtO-L5bD6uxpWy98htvJ65Ud9nNhoNj3LkpRlwkYHcJ_2ayx3nPSW9aasChPOk1USMWnvc3dsPOI6riLfMOFHpqn3ETyQOiVbzbey7xiooOO_Rz73Qyd3bNHF4zuO4gk86sin-Nw2P4V7WD2D41mrXn1zIua3yVjNiTgWs1td65vncDpFThMOys5iWTXs1jdU2NSCWKRYd78VRRmCQkS9ECvX_MFSEHjLouZwxRfw4-J8fjaJuisYIq-02kSFRWOQWItFVqnR2pBR9d74tCycCTKiY0-kBJ02mKDWzo6lT9SidFIiGciXcFjVFb4C4alfRmSkzKxUBZlFx3QxTVnDzvmFG8Cwn_f8ulXayMedgGmPWc6Y5R1mAzhldP53ZqHsUFGvf-XdROeokrKUmU-lLJU3umAXMouNWxhiRgoH8LHHNqeNxaclrsJ62-SJsex5EGEaQLoH-t4X91sI6yDR3WH7-s5vfoCHk_n0Mr_8evXtDRzxuFt5ybdwuFlv8R0cNOX2fVj4_wCAdwN4
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3Lb5wwEMZHTSpFufRddft0pSqnsMviB-bYPFap2kQrNZV6Q8Y26apdWC27h_z3nTGQLNf2gpAxQuYDzTcw_hngk7f4kGiVRUURi0hw73FPxZHVynPLtVYBmX_xPb36qc_OCZNzt9RXKNq3xWJc_VmOq8WvUFu5WtpJXyc2mV-eZklKmLDJypWTPXiI72wsdxL11vmmRIYJ_5RFEpFx7-fv6HhCbdSE-WFCm0xi70M44DLFeE0rs-8EqcDyHxjQYfnkTjyaPf6PkTyBR50JZZ_bLk_hga-ewdG8pVjfHrPr-0lZzTE7YvN7vvXtczi59DRdOBCe2aJqKL1vcGdTM3STbN19XmQuFIewumRL0_z2jqGIi6KmssUX8GN2fn16EXVLMURWSLGJCu2V8uhetCdajZQKg6u1yqauMCrgRKcWzYk3UvnES2n0lNtElM5w7jFQvoT9qq78K2AW-2VoSlymuSgwPBqyjWlKLDtjSzOCcX_v81VL3MinHci01y0n3fJOtxGckEJ3nQmYHRrq9U3e3ezci8Q5ntmUcyeskgWlklmsTKnQIQk_go-9vjm-YPTXxFS-3jZ5ojRlIGicRpAOhB9ccXgE9Q6o7k7f1_985gc4mJ_N8m9frr6-gUMadkuZfAv7m_XWv4O9xm3fh2f_L8W6Bfg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanistic+insights+into+the+rational+design+of+masked+antibodies&rft.jtitle=mAbs&rft.au=Orozco%2C+Carolina+T&rft.au=Bersellini%2C+Manuela&rft.au=Irving%2C+Lorraine+M&rft.au=Howard%2C+Wesley+W&rft.date=2022-12-31&rft.eissn=1942-0870&rft.volume=14&rft.issue=1&rft.spage=2095701&rft.epage=2095701&rft_id=info:doi/10.1080%2F19420862.2022.2095701&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1942-0862&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1942-0862&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1942-0862&client=summon